Targeted therapy in eosinophilic chronic obstructive pulmonary disease

• Published in: ERJ open research 2021-04, Vol.7 (2), p.437-2020
• Main Authors: Fieldes, Mathieu, Bourguignon, Chloé, Assou, Said, Nasri, Amel, Fort, Aurélie, Vachier, Isabelle, De Vos, John, Ahmed, Engi, Bourdin, Arnaud
• Format: Article
• Language: English
• Subjects: Human health and pathology; Immunology; Immunotherapy; Life Sciences; Pulmonology and respiratory tract; Review
• ISSN: 2312-0541; 2312-0541
• DOI: 10.1183/23120541.00437-2020

Chronic obstructive pulmonary disease (COPD) is a common and preventable airway disease causing significant worldwide mortality and morbidity. Lifetime exposure to tobacco smoking and environmental particles are the two major risk factors. Over recent decades, COPD has become a growing public health problem with an increase in incidence. COPD is defined by airflow limitation due to airway inflammation and small airway remodelling coupled to parenchymal lung destruction. Most patients exhibit neutrophil-predominant airway inflammation combined with an increase in macrophages and CD8 T-cells. Asthma is a heterogeneous chronic inflammatory airway disease. The most studied subtype is type 2 (T2) high eosinophilic asthma, for which there are an increasing number of biologic agents developed. However, both asthma and COPD are complex and share common pathophysiological mechanisms. They are known as overlapping syndromes as approximately 40% of patients with COPD present an eosinophilic airway inflammation. Several studies suggest a putative role of eosinophilia in lung function decline and COPD exacerbation. Recently, pharmacological agents targeting eosinophilic traits in uncontrolled eosinophilic asthma, especially monoclonal antibodies directed against interleukins (IL-5, IL-4, IL-13) or their receptors, have shown promising results. This review examines data on the rationale for such biological agents and assesses efficacy in T2-endotype COPD patients.